Cover Image
市場調查報告書

老年癡呆症的治療、診斷市場預測 (2016-2026年):主要企業的市場機會

Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies

出版商 Visiongain Ltd 商品編碼 288683
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老年癡呆症的治療、診斷市場預測 (2016-2026年):主要企業的市場機會 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies
出版日期: 2016年05月10日 內容資訊: 英文 200 Pages
簡介

2015年的全球老年癡呆症治療、診斷市場規模為70億美元,過去數年持續持平的狀態。在預測期間中後半預測相繼有新藥銷售,預計後半的收益成長幅度擴大。

本報告提供老年癡呆症的治療及診斷的藥物、診斷試驗、相關技術的市場調查,老年癡呆症概要,治療、診斷的整體市場成長推進因素、阻礙要素分析,老年癡呆症治療藥市場變化與預測,主要企業及主要藥物,開發平台趨勢,診斷市場變化與預測,生物標記、影像、其他技術趨勢,主要企業及主要產品,主要國家市場的趨勢、預測,定性分析,專家的採訪等彙整資料。

第1章 報告概要

第2章 老年癡呆症:簡介

  • 神經退化性疾病
    • 所謂老年癡呆症
    • 原因
    • 管理
    • 社會經濟影響
    • 診斷

第3章 老年癡呆症的治療、診斷:市場預測

  • 市場成果
  • 市場預測
  • 促進成長要素、阻礙要素

第4章 老年癡呆症治療藥:市場預測

  • 目前方法和未滿足需求
  • 市場成果
  • 主要藥物的佔有率的變化與預測
  • 市場預測
  • Namenda
  • Aricept
  • Exelon
  • 開發平台
  • 腦深部刺激
  • 近幾年的研究

第5章 老年癡呆症治療藥:主要企業

  • Pfizer, Inc
  • Eisai
  • Forest Laboratories (Acquired by Actavis)
  • Lundbeck A/S
  • Daiichi Sankyo
  • Novartis AG
  • TauRx
  • vTv Therapeutics
    • 銷售額
    • 主要產品等

第6章 老年癡呆症的診斷:市場預測

  • 對有效診斷的大需求
  • 診斷市場成果
  • 市場佔有率的變化與預測
  • 市場規模的變化與預測
  • 老年癡呆症診斷新的標準和指南
  • 生物標記
    • 主要企業
  • 診斷影像技術的進步
    • 結構影像
    • 功能影像
    • 分子影像技術
  • 開發中的其他診斷技術
    • CSF蛋白質
    • 血液為基礎的生物標記
    • 遺傳的風險分析
    • 眼的檢驗
    • 奈米粒子
  • 診斷市場主要企業
    • Eli Lilly
    • Amarantus BioScience Holdings, Inc.
    • Piramal Enterprises
    • GE Healthcare
    • Navidea
    • DiaGenic
      • 銷售額
      • 產品
      • 配合措施等

第7章 主要國家市場預測

  • 市場詰問:各地區明細
  • 市場預測:各地區明細
  • 主要國家市場的市場佔有率的轉變、預測
  • 美國
  • 歐洲
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 英國
    • 其他
  • 日本
  • 中國
  • 印度
  • 巴西
  • 俄羅斯
  • 其他

第8章 定性分析

  • SWOT分析
  • 波特的五力分析

第9章 專家的見解

第10章 總論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0116

Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies - our new study reveals trends, R&D progress, and predicted revenues

Our new report discusses issues and events affecting the Alzheimer's disease therapeutics and diagnostics market. Our new report provides qualitative analyses to answer these key questions:

  • How is the Alzheimer's disease therapeutics and diagnostics market evolving?
  • What is driving and restraining the Alzheimer's disease therapeutics and diagnostics market growth?
  • Which type of diagnostics will be the main drivers of the overall market from 2016 to 2026?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Who are the leading Alzheimer's disease therapeutics and diagnostics companies, and what are their prospects over the forecast period?
  • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

Forecasts from 2016-2026 and other analyses show you commercial prospects

Our new report provides quantitative analyses to answer these key questions:

  • What are the market shares of the Alzheimer's therapeutics disease market and Alzheimer's diagnostics market in 2015?
  • How will each of the drugs in the Alzheimer's therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026?
  • What Alzheimer's disease drugs are in the development pipeline and what revenues will these drugs make when they come on the market?
  • How will each of Alzheimer's disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026?
  • How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:

  • Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
  • Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
  • The Alzheimer's Association Northern California and Northern Nevada

Many opportunities exist for diagnosis and treatment of Alzheimer's. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead

Discover sales predictions for the world market and submarkets

Along with revenue prediction of the overall world market, you see forecasts to 2026 for these two submarkets:

  • Medicines for Alzheimer's disease
  • Diagnostics for Alzheimer's (including biomarkers).

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Alzheimer's disease drugs

How will leading drugs perform to 2026 at world level? Our study predicts individual revenues of three products:

  • Namenda
  • Aricept
  • Exelon

And also three pipeline products:

  • Solanezumab
  • Gantenerumab
  • MK-8931

What are the prospects in the leading regions and countries?

Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015. The US remains the largest national market by value, accounting for 40% of global revenues.

In addition to analyses of the overall world market, you discover revenue forecasts for 12 leading national markets to 2026:

  • US
  • Japan
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • China
  • Brazil
  • Russia
  • India
  • Rest of the World

Leading companies and potential for market growth

In 2015, the overall world market for Alzheimer's disease therapeutics and diagnostics was worth $7.0bn, having experienced a plateau in revenue over recent years. Within this forecast period, revenue growth will increase in the second half of the forecast period due to the expected launch of new drugs. There are around 9 drugs in phase III of clinical development.

Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:

  • Pfizer
  • Eisai
  • Actavis
  • Lundbeck
  • Daiichi Sankyo
  • Novartis
  • TauRx
  • vTv Therapeutics

In general, a company profile gives you the following information:

  • Revenue forecasts for Alzheimer's disease drugs from 2015 to 2026
  • Discussion of a company's activities and outlook
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What affects producers of those diagnostic tests and medicines?

Our report discusses issues and events affecting that industry and market from 2015, including these:

  • Research and development (R&D) - drugs, diagnostic tests, and related technologies
  • Disease prevalence - expanding patient populations
  • Disease-modifying drugs and obstacles to cures
  • Regulatory guidelines - changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer's:

  • Needs for Alzheimer's treatments
  • Drugs and related technologies to transform the market
  • Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
  • Diagnostic tests in development
  • Deep brain stimulation (functional neuromodulation)
  • Intellectual property (IP), licensing agreements and partnerships.

Our 200-page report provides 132 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Benefit your work now through our updated study, gaining original industry and market analysis:

  • Revenues for Alzheimer's disease therapeutics and diagnostics market to 2026 at world level, also for Alzheimer's drug submarket and Diagnostics submarket (Diagnostics Biomarkers and Others) and 3 medicines - assess outlooks for development, production, marketing and sales
  • Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
  • Prospects for established competitors, rising companies and new entrants - explore portfolios, technologies, results, strategies, R&D and outlooks for success
  • Analysis and forecast for Alzheimer's pipeline drugs and diagnostics - uncover pipeline drugs, diagnostics, their forecast and recent development status
  • Discussions of research and development - see progress in that industry, finding technological, clinical and commercial outlooks and opportunities
  • Opinions from companies and other organisations - discover, through three interviews, views to help you stay ahead in knowledge
  • Analysis of what stimulates and restrains that Alzheimer's disease therapeutics and diagnostics market - assess challenges and strengths, helping you compete and gain advantages.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The Alzheimer's Disease Therapeutics and Diagnostics Market Overview
  • 1.2. The Alzheimer's Disease Therapeutics and Diagnostics Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Alzheimer's Disease: An Introduction

  • 2.1. Neurodegenerative Diseases
    • 2.1.1. What is Alzheimer's Disease?
    • 2.1.2. What Causes Alzheimer's Disease?
    • 2.1.2.1. Alzheimer's Disease: Type 3 Diabetes?
    • 2.1.3. Management of Alzheimer's Disease
    • 2.1.4. The Socio-Economic Impact of Alzheimer's Disease
    • 2.1.5. Diagnosis of Alzheimer's Disease

3. Alzheimer's Disease Therapeutics and Diagnostics Market 2016-2026

  • 3.1. Alzheimer's Disease Therapeutics and Diagnostics Market, 2015
  • 3.2. Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
    • 3.2.1. The Market Has Been Left Exposed to Intensified Generic Competition
    • 3.2.2. Healthcare Costs for Alzheimer's Disease Will Surpass All Other Medical Expenses
    • 3.2.3. New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
  • 3.3. Drivers and Restraints

4. The Alzheimer's Disease Drugs Market, 2016-2026

  • 4.1. Current Approaches and Unmet Needs in the Treatment of Alzheimer's disease
  • 4.2. The Alzheimer's Disease Drugs Market, 2015
  • 4.3. Changing Market Shares of the Leading Alzheimer's Disease Drugs, 2016-2026
  • 4.4. The Alzheimer's Disease Drugs Market Forecast 2016-2026
  • 4.5. Namenda
    • 4.5.1. Namenda Sales Forecast, 2016-2026
  • 4.6. Aricept
    • 4.6.1. Aricept Sales Forecast, 2016-2026
  • 4.7. Exelon
    • 4.7.1. Exelon Sales Forecast, 2016-2026
  • 4.8. Alzheimer's Disease Drugs Pipeline, 2015
    • 4.8.1. New Guidelines: FDA to Relax Rules for the Approval of Alzheimer's Drugs
    • 4.8.2. Will Novel Drug Development Strategies Prove Successful?
    • 4.8.3. Solanezumab (Eli Lilly)
      • 4.8.3.1. Solanezumab Sales Forecast 2016-2026
    • 4.8.4. Gantenerumab (Roche)
      • 4.8.4.1. Gantenerumab Pipeline Forecast, 2015-2026
    • 4.8.5. MK-8931 (Merck)
      • 4.8.5.1. The MK-8931 Pipeline Forecast, 2015-2026
    • 4.8.6. Lu AE58054 (Lundbeck)
    • 4.8.7. TTP488 (TransTechPharma)
    • 4.8.8. LMTX (TauRx)
    • 4.8.9. EVP-6124 (Forum Pharmaceuticals)
    • 4.8.10. Axona (Accera)
    • 4.8.11. AD-4833 (Takeda Pharmaceuticals)
  • 4.9. Deep Brain Stimulation (Functional Neuromodulation)
  • 4.10. Recent Research on Alzheimer's Disease

5. Leading Companies in the Alzheimer's Disease Drugs Market, 2015

  • 5.1. Pfizer, Inc
    • 5.1.1. Sales and Recent Performance Analysis, 2015
    • 5.1.2. Pfizer: Aricept
    • 5.1.3. Pfizer: R&D Capabilities and Alzheimer's Disease Drug Candidates
  • 5.2. Eisai
    • 5.2.1. Sales and Recent Performance Analysis, 2015
    • 5.2.2. Eisai: Aricept
    • 5.2.3. Eisai: R&D Capabilities and Alzheimer's Disease Drug Candidates
    • 5.2.4. Collaboration with Biogen
    • 5.2.5. Partnership with GE Healthcare for Diagnostic Development
  • 5.3. Forest Laboratories (Acquired by Actavis)
    • 5.3.1. Acquisition by Actavis
    • 5.3.2. Forest: Namenda
    • 5.3.3. Namenda's Sales and Recent Performance Analysis, 2014
  • 5.4. Lundbeck A/S
    • 5.4.1. Sales and Recent Performance Analysis, 2014
    • 5.4.2. Lundbeck: R&D Capabilities
    • 5.4.3. Lundbeck's Alzheimer's Disease Drug Pipeline
    • 5.4.4. Lundbeck: Ebixa
  • 5.5. Daiichi Sankyo
    • 5.5.1. Financial Sales and Recent Performance, 2015
    • 5.5.2. Daiichi Sankyo: Memary
  • 5.6. Novartis AG
    • 5.6.1. Sales and Recent Performance Analysis
    • 5.6.2. Novartis: Exelon
    • 5.6.3. eHealth Programme Delivering Innovation
    • 5.6.4. Novartis: Alzheimer's Disease Drug Pipeline
  • 5.7. TauRx
    • 5.7.1. Partnership with Bayer Schering Pharma AG
  • 5.8. vTv Therapeutics
    • 5.8.1. TTP Translational Technology
    • 5.8.2. vTv Therapeutics: Alzheimer's Disease Pipeline Portfolio

6. The Alzheimer's Disease Diagnostics Market, 2015-2026

  • 6.1. There is Still a Strong Market Need for Effective Diagnosis
  • 6.2. The Alzheimer's Disease Diagnostics Market, 2015
  • 6.3. Changing Market Shares of Leading Alzheimer's Diagnostic Markets, 2015-2026
  • 6.4. The Alzheimer's Diagnostics Market, 2015-2026
  • 6.5. New Criteria and Guidelines to Diagnose Alzheimer's Disease
  • 6.6. Biomarkers for Alzheimer's Disease
    • 6.6.1. Leading Companies Pursuing Novel Biomarker Development Strategies
  • 6.7. Alzheimer's Disease: Advances in Diagnostic Imaging Technologies
    • 6.7.1. Structural Imaging
    • 6.7.2. Functional Imaging
    • 6.7.3. Molecular Imaging Technologies
      • 6.7.3.1. Pittsburgh Compound B (PIB) (GE Healthcare)
      • 6.7.3.2. Florbetapir F18 (18F-AV-45) (Eli Lilly)
      • 6.7.3.3. Flutemetamol (GE Healthcare)
      • 6.7.3.4. Florbetaben (Piramal Imaging)
  • 6.8. Other Alzheimer's Diagnostics in Development
    • 6.8.1. CSF Proteins
    • 6.8.2. Blood Based Biomarkers for Alzheimer's Disease
    • 6.8.3. Genetic Risk Profiling
    • 6.8.4. Eye Tests
    • 6.8.5. Nanoparticles
  • 6.9. Leading Companies in the Alzheimer's Disease Diagnostics Market, 2015
    • 6.9.1. Eli Lilly
      • 6.9.1.1. Recent Performance and Sales Analysis, 2015
      • 6.9.1.2. Alzheimer's Disease Research Effort
      • 6.9.1.3. Solanezumab
      • 6.9.1.4. Amyvid (Florbetapir F18)
      • 6.9.1.5. Amyvid Receives Marketing Authorization from the European Commission
      • 6.9.1.6. LY-2886721: Terminated Drug
      • 6.9.1.7. LY3002813: Phase I
      • 6.9.1.8. Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
    • 6.9.2. Amarantus BioScience Holdings, Inc.
      • 6.9.2.1. Recent Performance and Sales Analysis, 2014
      • 6.9.2.2. LymPro
      • 6.9.2.3. Intellectual Property Acquisitions
    • 6.9.3. Piramal Enterprises
      • 6.9.3.1. Piramal Imaging SA
      • 6.9.3.2. U.S. and EMA Approval of Florbetaben
      • 6.9.3.3. Manufacturing and Distribution Agreements
    • 6.9.4. GE Healthcare
      • 6.9.4.1. GE's Commitment to Imaging Research in the Alzheimer's Field
      • 6.9.4.2. Regulatory Approval of Flutemetamol
      • 6.9.4.3. Licensing Agreements for Flutemetamol
    • 6.9.5. Navidea
      • 6.9.5.1. NAV4694 (Fluorine-18)
      • 6.9.5.2. Collaboration Agreements
      • 6.9.5.3. NAV4694 Clinical Development
    • 6.9.6. DiaGenic

7. The Leading National Markets, 2015-2026

  • 7.1. Regional Breakdown of the Global Alzheimer's Disease Therapeutics and Diagnostic Market, 2015
    • 7.1.1. The US, Japan and Europe Represent More than 80% of the Total Market
  • 7.2. The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Forecast, 2015-2026
  • 7.3. Changing Market Shares of Leading National Markets 2015-2026
  • 7.4. The US Alzheimer's Disease Therapeutics and Diagnostics Market, 2015-2026
    • 7.4.1. One in Nine Over the Age of 65 has AD in the US
    • 7.4.2. The US Will Remain the Largest Market Over the Forecast Period
  • 7.5. The European Alzheimer's Disease Therapeutics and Diagnostics Market, 2015-2026
    • 7.5.1. The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
    • 7.5.2. The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
    • 7.5.3. The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
    • 7.5.4. The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
    • 7.5.5. The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
    • 7.5.6. The Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
  • 7.6. The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
  • 7.7. The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
  • 7.8. The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
  • 7.9. The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
  • 7.10. The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026
  • 7.11. The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2015-2026

8. Qualitative Analysis of the Alzheimer's Disease: Therapeutics and Diagnostics Market, 2016-2026

  • 8.1. SWOT Analysis
  • 8.2. Strengths
    • 8.2.1. Alzheimer's Disease is a High Profile Disease
    • 8.2.2. Expanding Patient Population
    • 8.2.3. Strong R&D Pipeline in Both Sectors of the Market
  • 8.3. Weaknesses
    • 8.3.1. Current Drugs Only Treat the Symptoms of Alzheimer's Disease
    • 8.3.2. Recent Failures of Promising Drug Candidates in Clinical Trials
    • 8.3.3. Poor Macroeconomic Conditions in Key Regions of the Market
  • 8.4. Opportunities
    • 8.4.1. Regulations Seeking Improved Standards of Alzheimer's Disease Drug Development
    • 8.4.2. Neurodegenerative Diseases Have Strong R&D
    • 8.4.3. Emerging Markets Will Help Drive the Market
    • 8.4.4. Advances in Diagnostic Technologies Will Improve Drug Market Penetration
  • 8.5. Threats
    • 8.5.1. Patent Expiries Will Lead to Further Generic Competition
    • 8.5.2. New AD Therapies Face Political, Commercial and Social Pressures
  • 8.6. Porter's Five Force Analysis
    • 8.6.1. Rivalry Among Competitors
    • 8.6.2. Threats of New Entrants
    • 8.6.3. Powers of Suppliers
    • 8.6.4. Bargaining Power of Buyers
    • 8.6.5. Threat of Substitutes

9. Research Interviews from Our Survey

  • 9.1. Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
    • 9.1.1. Alzheimer's Treatment in Late Stage Development
    • 9.1.2. Alzheimer's Severe Under diagnosis
    • 9.1.3. The Benefits of Alzheimer's Diagnosis: A Future Prospect
    • 9.1.4. Alzheimer's Treatment: The Greatest Challenge
  • 9.2. Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
    • 9.2.1. Ultra Sensitive Automated Immunoassay Platform for Alzheimer's
    • 9.2.2. Alzheimer's Disease Diagnosis Biomarkers
    • 9.2.3. Quanterix: Future Developments
  • 9.3. The Alzheimer's Association Northern California and Northern Nevada
    • 9.3.1. Alzheimer's Treatment in Late Stage Development
    • 9.3.2. Novel Biomarkers: Critical for Alzheimer's Diagnosis
    • 9.3.3. A Push to Improve the Success of Alzheimer's Research

10. Conclusion

  • 10.1. Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
  • 10.2. Disease Modifying Drugs Will Transform the Declining Alzheimer's Market
  • 10.3. Demographics Will Help Drive the Market Over the Forecast Period
  • 10.4. Medicines and Diagnostic Tests for Alzheimer's Disease Hold Great Potential from 2015 to 2026
  • 10.5. Research for Alzheimer's Happening all Over the World

List of Tables

  • Table 1.1: The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 2.1: Leading Sectors in the Neurodegenerative Disease Market, 2015
  • Table 2.2: Imaging Technologies Used in Alzheimer's Research, 2015
  • Table 3.1: The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2015
  • Table 3.2: Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2016-2026
  • Table 3.3: The Alzheimer's Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2015
  • Table 4.1: The Alzheimer's Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2015
  • Table 4.2: Market Shares (%) of the Leading Alzheimer's Drugs, 2015, 2020, 2026
  • Table 4.3: The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.4: Namenda: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.5: Aricept: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.6: Exelon: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.7: Selected List of Alzheimer's Disease Drugs in the Pipeline, 2016
  • Table 4.8: Continued Selected List of Alzheimer's Disease Drugs in the Pipeline, 2016
  • Table 4.9: Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.10: Roche: Gantenerumab Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 4.11: Merck: MK-8931 Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.1: Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2015
  • Table 5.2: Pfizer: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.3: Pfizer: Alzheimer's Disease Drug Pipeline, 2015
  • Table 5.4: Eisai: Aricept Regional Sales ($m), AGR (%), 2013
  • Table 5.5: Eisai: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.6: Biogen: Alzheimer's Disease Drugs Pipeline, 2015
  • Table 5.7: Forest: Namenda's Historical Revenues ($bn) and AGR (%), 2010-2014
  • Table 5.8: Forest: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.9: Lundbeck: Revenue ($bn) and Revenue Share (%) by Region, 2014
  • Table 5.10: Ebixa: Revenue ($bn) and Revenue Share (%) by Region, 2014
  • Table 5.11: Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.12: Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), CAGR (%), 2015-2026
  • Table 5.13: Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2015
  • Table 5.14: vTv Therapeutics : Alzheimer's Disease Drugs Pipeline, 2015
  • Table 6.1: The Alzheimer's Disease Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2015
  • Table 6.2: Market Shares (%) of the Leading Alzheimer's Diagnostics Markets, 2015, 2020 and 2026
  • Table 6.3: The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment, 2015-2026
  • Table 6.4: Key Alzheimer's Diagnostic Tests in Development, 2015
  • Table 6.5: (Continued) Key Alzheimer's Diagnostic Tests in Development, 2015
  • Table 6.6: DiaGenic: Alzheimer's Disease Diagnostics Pipeline and Current Developments, 2015
  • Table 7.1: The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Share (%) by Region, 2015
  • Table 7.2: The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2015-2026
  • Table 7.3: Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast CAGR (%), 2013-2018, 2018-2024, 2015-2026
  • Table 7.4: Market Shares (%) of the Leading Regional Alzheimer's Disease Therapeutics and Diagnostics Markets, 2015, 2020 and 2026
  • Table 7.5: The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.6: The European Alzheimer's Therapeutics and Diagnostics Market: Revenue ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2015
  • Table 7.7: The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.8: The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.9: The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.10: The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.11: The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.12: The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.13: The Rest of Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.14: The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.15: The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.16: The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.17: The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.18: The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 7.19: The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR(%), 2015-2026
  • Table 8.1: SWOT Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2015
  • Table 10.1: The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2015, 2020 and 2026 and CAGR (%) 2015-2020 and 2020-2026 by Region
  • Table 10.2: The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2015, 2020 and 2026

List of Figures

  • Figure 1.1: Alzheimer's Disease Therapeutics and Diagnostics: Overview of Submarkets and Segments
  • Figure 3.1: The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Sector, 2015
  • Figure 3.2: The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Market Share (%) by Sector, 2015
  • Figure 3.3: The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 4.1: The Alzheimer's Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2015
  • Figure 4.2: The Alzheimer's Disease Drugs Market: Market Shares (%) by Leading Drugs, 2015
  • Figure 4.3: The Alzheimer's Therapeutics Market: Market Shares (%) by Drug, 2020
  • Figure 4.4: The Alzheimer's Therapeutics Market: Market Shares (%) by Drug, 2026
  • Figure 4.5: The Alzheimer's Disease Drugs Market Forecast: Revenue ($bn), 2015-2026
  • Figure 4.6: Namenda: Sales Forecast ($bn), 2015-2026
  • Figure 4.7: Aricept: Sales Forecast ($bn), 2015-2026
  • Figure 4.8: Exelon: Sales Forecast ($bn), 2015-2026
  • Figure 4.9: Eli Lilly: Solanezumab Sales Forecast ($bn), 2015-2026
  • Figure 4.10: Roche: Gantenerumab Sales Forecast ($bn), 2015-2026
  • Figure 4.11: Merck: MK-8931 Sales Forecast ($bn), 2015-2026
  • Figure 5.1: Pfizer: Historical Revenues ($bn), 2012-2015
  • Figure 5.2: Pfizer: Revenues ($bn) by Sector, 2015
  • Figure 5.3: Pfizer: Revenue Shares (%) by Sector, 2015
  • Figure 5.4: Pfizer: Aricept Sales Forecast ($bn), 2015-2026
  • Figure 5.5: Pfizer: Historical R&D Expenditure ($bn), 2013-2015
  • Figure 5.6: Eisai: Aricept Sales Forecast ($bn), 2015-2026
  • Figure 5.7: Eisai: Historical R&D Expenditure ($bn), 2013-2014
  • Figure 5.8: Forest: Namenda's Historical Revenue ($bn), 2010-2014
  • Figure 5.9: Forest: Namenda Sales Forecast ($bn), 2015-2026
  • Figure 5.10: Lundbeck: Revenue Share (%) by Region, 2014
  • Figure 5.11: Lundbeck: Revenue Share ($bn) by Region, 2014
  • Figure 5.12: Lundbeck: R&D Expenditure ($bn), 2013-2014
  • Figure 5.13: Ebixa: Revenue ($bn) by Region, 2014
  • Figure 5.14: Ebixa: Revenue Shares (%) by Region, 2014
  • Figure 5.15: Ebixa: Sales Forecast ($bn), 2015-2026
  • Figure 5.16: Daiichi Sankyo: Historical Revenue ($bn), 2012-2014
  • Figure 5.17: Daiichi Sankyo: Memary Historical Revenue ($bn), 2013-2014
  • Figure 5.18: Daiichi Sankyo: Memary Sales Forecast ($bn), 2015-2026
  • Figure 5.19: Novartis: Historical Revenues ($bn), 2012-2015
  • Figure 5.20: Novartis: Revenues ($bn) by Segment, 2015
  • Figure 5.21: Novartis: Revenue Shares(%) by Segment, 2015
  • Figure 5.22: Exelon: Revenue Shares (%) by Region, 2013
  • Figure 6.1: The Alzheimer's Disease Diagnostics Market: Revenues ($bn) by Segment, 2015
  • Figure 6.2: The Alzheimer's Disease Diagnostics Market: Market Shares (%) by Segment, 2015
  • Figure 6.3: The Alzheimer's Diagnostics Market: Market Share (%) by Segment, 2020
  • Figure 6.4: The Alzheimer's Diagnostics Market: Market Share (%) by Segment, 2026
  • Figure 6.5: The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2015-2026
  • Figure 6.6: Eli Lilly: Historical Revenue ($bn), 2012-2015
  • Figure 6.7: AmarantusBioScience: R&D Costs ($m), 2013-2014
  • Figure 7.1: The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2015
  • Figure 7.2: The Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2015
  • Figure 7.3: Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2015-2020
  • Figure 7.4: Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2020-2026
  • Figure 7.5: Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2015-2026
  • Figure 7.6: The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2020
  • Figure 7.7: The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2026
  • Figure 7.8: The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.9: The US Demographics: No. of People Aged 65 or Over, 2015 and 2026 Forecast
  • Figure 7.10: The European Alzheimer's Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Leading Countries, 2015
  • Figure 7.11: The European Alzheimer's Disease Therapeutics and Diagnostics Market : Market Shares (%) by Leading Countries, 2015
  • Figure 7.12: The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.13: The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.14: The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.15: The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.16: The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.17: The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.18: The Other European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn),2015-2026
  • Figure 7.19: The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.20: The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.21: China's Historical Healthcare Expenditure ($bn), 2001-2010
  • Figure 7.22: The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.23: The Brazilian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($m), 2015-2026
  • Figure 7.24: The Russian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.25: The Rest of the World Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2015-2026
  • Figure 8.1: The Global Over 65 Population: Forecast (millions), 2010-2050
  • Figure 8.2: Porter's Five Force Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2015
  • Figure 10.1: The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2015, 2020 and 2026
  • Figure 10.2: The Global Alzheimer's Disease Therapeutics and diagnostics Market ($bn) by Segment, 2015, 2020 and 2026

Companies Listed

  • AbbVie
  • AC Immune
  • Acadia Pharmaceuticals
  • Accera
  • Actavis
  • Adamas Pharmceuticals
  • Affiris
  • Amarantus BioSciences
  • Amorphis
  • Archer Pharmaceuticals
  • Astex
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avineuro Pharmaceuticals
  • Baxter
  • Bayer
  • Bayer Schering Pharma
  • Biogen
  • bioMerieux
  • Ceregene
  • Chiesi Farmaceutici
  • Cognoptix
  • Cytos
  • Daiichi Sankyo
  • DiaGenic
  • Eisai
  • Elan
  • Eli Lilly
  • EnVivo Pharmaceuticals
  • Forest Laboratories
  • Forum Pharmaceuticals
  • Foundation Medical Partners
  • Functional Neuromodulation
  • GE Healthcare
  • General Electric
  • Genervon Biopharmaceuticals
  • Genesys Capital
  • GSK
  • Hisamitsu Pharmaceutical
  • Humanetics
  • IBA Molecular
  • J&J
  • Janssen Alzheimer Immunotherapy Research & Development
  • Janssen Pharmaceutical K. K
  • Kareus Therapeutics
  • LabCorp
  • Luminex
  • Lundbeck
  • Medtronic
  • Merck & Co
  • Merz
  • Meso Scale Diagnostics
  • Metabolic Solutions Development Company
  • MorphoSys
  • Nanotherapeutics
  • Navidea
  • NextGen Sciences
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceutical
  • OPKO
  • Ortho Clinical Diagnostics
  • Otsuka Pharmaceutical
  • Oxford BioDynamics
  • Par Pharmaceuticals
  • Pfizer
  • Piramal Enterprises
  • Piramal Imaging
  • Proteome Sciences
  • ProteoTech
  • Proterra
  • QR Pharma
  • Quanterix
  • Raptor Pharmaceutical
  • Resverlogix
  • Roche
  • Roche Diagnostics
  • Saladax
  • Sangamo BioSciences
  • Sanofi
  • sGC Pharma
  • Shionogi
  • Shire
  • Siemens Medical Solutions USA
  • Somalogic
  • Sonexa Therapeutics
  • Sun Pharma
  • T3D Therapeutics
  • Takeda
  • Targacept
  • TauRx
  • Toyama Chemical
  • Transition Therapeutics
  • TransTech Pharma
  • United Biomedical
  • VIVUS
  • Wyeth

Organisations mentioned in the report

  • Alzheimer's Association International Conference (AAIC)
  • Alzheimer's Research UK
  • Assogenerici (Italy)
  • Cambridge University
  • Cleveland Clinic Lou Ruvo Center for Brain Health
  • Dementia UK
  • French Economic Committee
  • King's College London
  • Ministry of Health, Labout and Welfare (MHLW) (Japan)
  • National Health Services (Italy)
  • National Health Services (NHS) (UK)
  • National Institute of Clinical Excellence (NICE)
  • National Institute of Health (NIH)
  • The Alzheimer's Association
  • The Centers for Medicare and Medicaid Services (CMS)
  • The Central Drug Standard Control Organisation (CDSCO)
  • The Duke University
  • The European Commission
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)
  • The Food and Drug Administration FDA (US)
  • The Health and Social Care Information Centre
  • The National Institute of Aging (NIA)
  • The Supreme Court of Japan
  • The University of Aberdeen
  • The University of Cologne
  • The University of Pittsburgh
  • Trinity College Dublin
  • United Nations (UN)
  • World Health Organisation (WHO)
Back to Top